TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21131864
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of whey protein (PRO)
Study: 21131864
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of whey protein plus 50 g of maltodextrin (PRO+CARB)
Study: 21131864
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of CHO with 25 g of protein (PRO+CARB)
Study: 19438818
Drug: Intermittent terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent terbinafine (TOT) 250 mg/day for 4 weeks followed by 4 weeks off, then 4 weeks of 250 mg/day
Study: 19438818
Drug: Continuous terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terbinafine (CTERB) 250 mg/day for 12 weeks
Study: 19438818
Drug: Itraconazole (III)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole (III) pulse of 200 mg twice daily for 7 days on, 21 days off, three pulses
Study: 16484854
Drug: Cytostatic antineoplastic
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytostatic antineoplastic agents
Study: 15051778
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron (iron dextran total dose infusion)
Study: 15051778
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (325 mg twice daily)
Study: 9152680
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 209 micromol of Vitamin A
Study: 7957533
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg orlistat
Study: 7957533
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg orlistat
Study: 7957533
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg orlistat
Study: 7957533
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg orlistat
Study: 31990087
Drug: TAK‐954 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK‐954 (0.5 mg intravenous over 1 hour)
Study: 31990087
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg intravenous 4 times/d)
Study: 29164826
Drug: Buffered 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution
Study: 22092688
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch (pulsed electromagnetic energy)
Study: 18503714
Drug: Ibuprofen (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (7 mg/kg body weight, every eight hours)
Study: 8712823
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 2 courses of chemotherapy with CDDP and VDS
Study: 8712823
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: UFT daily for 1 year after 2 courses of CDDP
Study: 8712823
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Intrapleural administration of OK-432 after lung resection, then UFT and OK-432 once every 2 weeks for 1 year
Study: 8712823
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (low-grade TP <6.0 g/dl or low response of PPD skin reaction <12mm)
Study: 1574292
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of sodium hyaluronate (HA) in group B (11 patients)
Study: 3904559
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d for 8 weeks)
Study: 30782904
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 daily supplements (50 μg) to pregnant women
Study: 17513708
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin regimen (glargine and glulisine)
Study: 17513708
Drug: Sliding-scale regular
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding-scale regular insulin (SSI)
Study: 15390055
Drug: 1.125 mg
Normalized name: Ascorbic Acid/Calcium Pantothenate/Folic Acid/Kava/Lecithin/Niacin/St John's Wort/Thiamine 60 MG-5 MG-0.1 MG-100 MG-15 MG-10 MG-225 MG-1.125 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.125 mg rotigotine (RTG) per day
Study: 15390055
Drug: 2.25 mg
Normalized name: serine 2.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 mg rotigotine (RTG) per day
Study: 15390055
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg rotigotine (RTG) per day
Study: 15390055
Drug: All rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All rotigotine doses
Study: 15390055
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg rotigotine (RTG)
Study: 9882084
Drug: Dexketoprofen 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 12.5 mg
Study: 9882084
Drug: Dexketoprofen 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 12.5 mg and 25 mg, Ketoprofen 50 mg
Study: 8018673
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of beta-carotene
Study: 31172415
Drug: IFN and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN and vaccine for 48 weeks plus IL-2 for 12 weeks (group III)
Study: 31172415
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (IFN and vaccine plus IL-2) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Study: 31172415
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (IFN) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Study: 31172415
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (ETV) among patients with baseline HBsAg titers ranging from 100 to 1500 IU/mL
Study: 26369563
Drug: Tiotropium HandiHaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium HandiHaler® 18 μg
Study: 22231764
Drug: Ointment bandage
Normalized name: New-Skin Liquid Bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment bandage (OB)
Study: 22231764
Drug: IV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV therapy alone
Study: 15650310
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with grass pollen
Study: 12404199
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg
Study: 12404199
Drug: Estrogen transdermal
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen transdermal patch (ETP) 50 microg
Study: 10090431
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate ophthalmic gel-forming solution 0.5% (timolol gel) once daily
Study: 10090431
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate ophthalmic solution 0.5% (timolol solution) twice daily
Study: 7286051
Drug: Chlorthalidone 75
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 75 mg
Study: 19790150
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with CNI reduction or discontinuation
Study: 17846353
Drug: High-dose VIT100
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VIT100 (0.75 mg)
Study: 17846353
Drug: Low-dose VIT100
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VIT100 (0.15 mg)
Study: 15475528
Drug: Intra-arterial aminophylline
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial aminophylline (to block adenosine receptors)
Study: 8072818
Drug: Bivalent pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent pneumococcal capsular polysaccharide (CPS)‐protein conjugate vaccines with serotypes 6A and 23F
Study: 8072818
Drug: Bivalent pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent pneumococcal conjugate vaccine with native CPS directly linked to the carrier protein
Study: 8072818
Drug: Bivalent pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent pneumococcal conjugate vaccines with smaller CPS or a six‐carbon linker
Study: 8072818
Drug: Licensed pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed pneumococcal vaccine
Study: 3186274
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg naloxone i.v.
Study: 3186274
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg naloxone i.v.
Study: 28686535
Drug: PET-CT normalization
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-CT normalization before maintenance therapy
Study: 23782709
Drug: Individualized, meridian‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, meridian‐based syndrome differentiation and Sa‐am acupuncture treatment
Study: 23782709
Drug: Standard acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acupuncture treatment
Study: 23782709
Drug: No acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acupuncture treatment
Study: 21895884
Drug: entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone 200 mg with each levodopa dose
Study: 19108956
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Alcohol (0.33 ml alcohol/kg body weight)
Study: 19108956
Drug: Moderate Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Dose Alcohol (0.75 ml/kg)
Study: 11763935
Drug: 0.03% triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% triclosan mouthrinse (15 ml, twice daily for 21 days)
Study: 11763935
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse (15 ml, twice daily for 21 days)
Study: 8225695
Drug: silybin 240
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: silybin 240 mg b.i.d.
Study: 3544654
Drug: Femoxetine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine 600 mg
Study: 18695158
Drug: Carbidopa-levodopa 37.5/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa-levodopa 37.5/150 mg daily
Study: 18695158
Drug: Carbidopa-levodopa 75/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa-levodopa 75/300 mg daily
Study: 18695158
Drug: Carbidopa-levodopa 150/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa-levodopa 150/600 mg daily
Study: 9753211
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg/Kg intravenously
Study: 9753211
Drug: Ondansetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.2 mg/Kg intravenously
Study: 9753211
Drug: 0.07 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/Kg diazepam orally
Study: 3110315
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g preoperative oral dose)
Study: 3110315
Drug: Pivampicillin (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (high-dose short-term broad spectrum penicillin)
Study: 31028900
Drug: Upper-limb robotic-assisted
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper-limb robotic-assisted therapy (RAT)
Study: 24288364
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d) plus telmisartan (80 mg/d)
Study: 24288364
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d) plus irbesartan (300 mg/d)
Study: 24288364
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d) plus olmesartan (20 mg/d)
Study: 21399485
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 to 10 mg/d) for 6 months
Study: 18685810
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg every other day
Study: 9181906
Drug: Nephrectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days)
Study: 9181906
Drug: Nephrectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2
Study: 31965842
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052)
Study: 21716146
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m on days 1 and 8 every 21 days (Arm A)
Study: 21716146
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily (Arm B)
Study: 21716146
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 every 21 days and erlotinib 100 mg daily (Arm C)
Study: 17313002
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at Hegu (LI 4) and intravenous drip of oxytocin
Study: 17313002
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of oxytocin
Study: 1585959
Drug: Nonspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific treatment
Study: 3898891
Drug: Placebo bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bupivacaine injection
Study: 30458732
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition, followed on progression by fulvestrant
Study: 30458732
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment with a non-steroidal aromatase inhibitor, followed on progression by fulvestrant combined with CDK4/6 inhibition
Study: 25277144
Drug: Selexipag (400-1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (400-1,800 µg, twice daily for 3 days)
Study: 22402145
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to 7.5 mg/day in 7 weeks
Study: 17297026
Drug: Primaquine 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 210 mg
Study: 17297026
Drug: Primaquine 315
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 315 mg
Study: 17297026
Drug: Primaquine 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 420 mg
Study: 17297026
Drug: Weight-based primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based primaquine dose
Study: 9158465
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection alone
Study: 9158465
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection plus heat probe treatment
Study: 9158465
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection alone (subgroup with spurting haemorrhage)
Study: 9158465
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection plus heat probe treatment (subgroup with spurting haemorrhage)
Study: 8260854
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (fluticasone propionate [FP] 100 micrograms twice daily)
Study: 27690510
Drug: Solution hints
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution hints available
Study: 27690510
Drug: No solution
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No solution hints available
Study: 16781588
Drug: EPs 7630
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630 (30 drops three times daily for seven days)
Study: 16781588
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 drops three times daily for seven days)
Study: 6106612
Drug: Halazepam 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halazepam 120 mg
Study: 6106612
Drug: Halazepam 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halazepam 60 mg
Study: 16968580
Drug: Omalizumab add-on
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab add-on therapy
Study: 21434337
Drug: Nuanxin Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuanxin Capsule (NXC)
Study: 19376452
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (1500 mg per day)
Study: 19839182
Drug: Pravastatin-acetylsalicylic acid
Normalized name: pravastatin and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin-acetylsalicylic acid combination
Study: 11920767
Drug: 17-beta-estradiol matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol matrix patch (first patch worn for 4 days, second for 3 days, third for 4 days)
Study: 11920767
Drug: 17-beta-estradiol matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol matrix patch (control group without E(2) pretreatment)
Study: 8004359
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) alone
Study: 8004359
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) with Sho‐saiko‐to (TJ‐9)
Study: 8004359
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) with Rikkunshi‐to (TJ‐43)
Study: 8004359
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) with Sairei‐to (TJ‐114)
Study: 2620951
Drug: Intramuscular iron-dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron-dextran complex
Study: 2620951
Drug: Intravenous iron-dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron-dextran complex
Study: 22882007
Drug: Subconjunctival 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of surgery (Group 2)
Study: 18194593
Drug: Low-dose medical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose medical food emulsion (0.75 g GLA + 0.5 g EPA)
Study: 18194593
Drug: High-dose medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medical food emulsion (1.13 g GLA + 0.75 g EPA)
Study: 18194593
Drug: Low-dose medical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose medical food emulsion (EFF1009)
Study: 16407665
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (1 approximately 3 mg/kg/day for 3 days)
Study: 16407665
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous prednisolone)
Study: 8912147
Drug: Torasemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (40 mg)
Study: 6337700
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (120 mg in 50 ml saline) administered weekly for 6 weeks
Study: 31787586
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 4 g/d
Study: 26499756
Drug: Whey isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey isolate protein drink (12.5 g)
Study: 26499756
Drug: Whey isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey isolate protein drink (50 g)
Study: 26499756
Drug: Whey isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey isolate protein drink (75 g)
Study: 26499756
Drug: Whey isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey isolate protein drink (100 g)
Study: 26499756
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (20 g)
Study: 24374803
Drug: Glutamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 0.5 g/kg
Study: 24374803
Drug: 18AA‐II solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18AA‐II solution
Study: 16685547
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,000 mg day(-1))
Study: 10781923
Drug: Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3 mg/kg, Ketalar)
Study: 8834420
Drug: Buprenorphine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (average dose = 9.0 mg/day sublingually)
Study: 8834420
Drug: Methadone (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (average dose = 54 mg/day orally)